Clinical and Experimental Nephrology

, Volume 13, Issue 4, pp 397–401 | Cite as

Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma

  • Iris J. A. M. Jonkers
  • Marjolijn van Buren
Case Report


A 51-year-old man with immunoglobulin A (IgA) nephropathy developed metastatic renal-cell carcinoma of his native right kidney, 3.5 years post kidney transplant. At that time renal function was stable with the presence of only mild proteinuria. Shortly after chemotherapy with sorafenib [anti-vascular endothelial growth factor (VEGF)] was initiated, progressive renal impairment, hypertension, and nephrotic-range proteinuria developed. Allograft biopsy showed extensive IgA nephropathy. After withdrawal of the anti-VEGF therapy, however, renal function and blood pressure improved, and proteinuria diminished. Based on the clinical course and histopathological findings we hypothesize that sorafenib may induce nephrotic-range proteinuria and renal impairment, possibly through anti-VEGF-mediated effects on the progression of IgA nephropathy.


IgA nephropathy Proteinuria Sorafenib VEGF 



The authors thank Ingeborg Bajema for the provision of the figures.

Conflict of interest statement

None declared.


  1. 1.
    George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007;49:e23–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian S, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–34.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Eremina V, Jefferson JA, Kowaleska V, Hochster H, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–36.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV. 6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant. 2002;32:34–6.Google Scholar
  6. 6.
    Choy BY, Chan TM, Lo SK, Lo WK, Lai KN. Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant. 2003;11:2399–404.CrossRefGoogle Scholar
  7. 7.
    Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359–65.CrossRefPubMedGoogle Scholar
  8. 8.
    Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol. 2007;5:287–93.CrossRefGoogle Scholar
  10. 10.
    de Fijter JW, Mallat MJ, Doxiadis II, Ringers J, Rosendaal FR, Claas FH, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol. 2001;12:1538–46.PubMedGoogle Scholar
  11. 11.
    Kiattisunthorn K, Premasathian N, Wongwiwatana A, Parichatikanond P, Cheunsuchon B, Vasuvattakul S. Evaluating the clinical course and prognostic factors of posttransplantation immunoglobulin A nephropathy. Transplant Proc. 2008;40(7):2349–54.CrossRefPubMedGoogle Scholar
  12. 12.
    Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest. 1999;104:913–23.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yuan HT, Tipping PG, Li XZ, Long DA, Woolf AS. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int. 2002;61:2078–89.CrossRefPubMedGoogle Scholar
  14. 14.
    Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol. 1996;7:661–6.PubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2009

Authors and Affiliations

  • Iris J. A. M. Jonkers
    • 1
  • Marjolijn van Buren
    • 2
  1. 1.Department Nephrology C3-RLeiden University Medical CenterLeidenThe Netherlands
  2. 2.Department of Internal MedicineHaga ZiekenhuisThe HagueThe Netherlands

Personalised recommendations